To confirm the deleterious effect of TGF-β in our therapeutic models, we treated tumor-bearing mice (4T1, EMT6, as well as 2 other BC models: a luminal tumor model [TS/A], and a spontaneous model [mouse mammary tumor virus [MMTV] and polyomavirus middle T antigen [PYMT]) with an anti–TGF-β antibody. The gene discussed is TGFB1; the disease is breast cancer.